2007
Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer
Pomerantz M, Manola J, Taplin M, Bubley G, Inman M, Lowell J, Beard C, Kantoff P, Oh W. Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer. Journal Of Urology 2007, 177: 2146-2150. PMID: 17509304, DOI: 10.1016/j.juro.2007.01.119.Peer-Reviewed Original ResearchConceptsAndrogen-independent prostate cancerIndependent prostate cancerProstate specific antigenProstate cancerSpecific antigenDose armProgressive androgen-independent prostate cancerAdministered to most patientsStudy of low doseAndrogen-independent diseaseHigh dose armLow dose armProphylactic breast irradiationPhase II studyMonths of treatmentDehydroepiandrosterone sulfate levelsRisk of thromboembolismWarfarin 1 mgBreast irradiationThromboembolic eventsThromboembolic complicationsTherapeutic optionsConjugated estrogensMost patientsPremarin
2006
Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC)
Pomerantz M, Manola J, Taplin M, Bubley G, Inman M, Lowell J, Kantoff P, Oh W. Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). Journal Of Clinical Oncology 2006, 24: 4560-4560. DOI: 10.1200/jco.2006.24.18_suppl.4560.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerLow dosesHigh dosesLD armProgressive androgen-independent prostate cancerHD armMedian time to progressionClinical predictors of responseStudy of low doseGrade 3 toxicityPatients treated with LDProphylactic breast irradiationPSA response rateTime to progressionIndependent prostate cancerPhase II studyStage of accrualPredictors of responseCorrelates of treatment responseWarfarin 1 mgDose of PremarinBreast irradiationProphylactic warfarinTransdermal estradiolMedian PSA
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply